Bio News
The U.S. Food and Drug Administration (FDA) has approved Mounjaro from Eli Lilly for an indication to reduce the risk of major cardiovascular events in patients with type 2 diabetes who are at risk of cardiovascular disease. In a phase 3 clinical trial, Mounjaro reduced the incidence of cardiovascular death, heart attack and stroke by 8% compared with Trulicity. With the approval, Eli Lilly will compete with Novo Nordisk’s Ozempic in the cardiovascular indication.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
